[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK1761520T3 - Kinaseinhibitorer - Google Patents

Kinaseinhibitorer

Info

Publication number
DK1761520T3
DK1761520T3 DK05766569T DK05766569T DK1761520T3 DK 1761520 T3 DK1761520 T3 DK 1761520T3 DK 05766569 T DK05766569 T DK 05766569T DK 05766569 T DK05766569 T DK 05766569T DK 1761520 T3 DK1761520 T3 DK 1761520T3
Authority
DK
Denmark
Prior art keywords
kinase inhibitors
formula
present
inhibitors
provides kinase
Prior art date
Application number
DK05766569T
Other languages
English (en)
Inventor
Dios Alfonso De
Tiechao Li
Cabrejas Luisa Maria Martin
Mark Andrew Pobanz
Chuan Shih
Yong Wang
Boyu Zhong
Jesus Andres Blas
De Uralde-Garmendia Beatriz Lopez
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP04380131A external-priority patent/EP1609789A1/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK1761520T3 publication Critical patent/DK1761520T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK05766569T 2004-06-23 2005-06-15 Kinaseinhibitorer DK1761520T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP04380131A EP1609789A1 (en) 2004-06-23 2004-06-23 Ureido-pyrazole derivatives and their use as kinase inhibitors
US59253904P 2004-07-30 2004-07-30
EP04380174 2004-08-23
US62249204P 2004-10-27 2004-10-27
PCT/US2005/021148 WO2006009741A1 (en) 2004-06-23 2005-06-15 Kinase inhibitors

Publications (1)

Publication Number Publication Date
DK1761520T3 true DK1761520T3 (da) 2008-10-27

Family

ID=43875180

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05766569T DK1761520T3 (da) 2004-06-23 2005-06-15 Kinaseinhibitorer

Country Status (9)

Country Link
US (1) US7767674B2 (da)
EP (1) EP1761520B1 (da)
AT (1) ATE400567T1 (da)
DK (1) DK1761520T3 (da)
ES (1) ES2308523T3 (da)
PL (1) PL1761520T3 (da)
PT (1) PT1761520E (da)
SI (1) SI1761520T1 (da)
WO (1) WO2006009741A1 (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005089380A2 (en) 2004-03-16 2005-09-29 The Regents Of The University Of California Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
WO2004089296A2 (en) 2003-04-03 2004-10-21 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
CA2584342C (en) 2004-10-20 2013-04-30 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
AR058128A1 (es) * 2005-10-28 2008-01-23 Lilly Co Eli Compuesto de pirazolil carbamato y formulacion farmaceutica que lo comprende
DOP2006000234A (es) * 2005-10-28 2007-05-31 Lilly Co Eli Inhibidores de cinasa
AR059826A1 (es) 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
US8236954B2 (en) * 2007-06-26 2012-08-07 Glaxosmithkline Llc Processes for preparing benzimidazole thiophenes
US8314091B2 (en) 2007-08-20 2012-11-20 Msd Oss B.V. N-benzyl,N'-arylcarbonylpiperazine derivatives
WO2009119534A1 (ja) 2008-03-26 2009-10-01 第一三共株式会社 新規テトラヒドロイソキノリン誘導体
TW201022230A (en) * 2008-08-28 2010-06-16 Organon Nv 1-(4-ureidobenzoyl)piperazine derivatives
CN102256964A (zh) 2008-10-02 2011-11-23 瑞斯比维特有限公司 p38MAP激酶抑制剂
GB0818033D0 (en) 2008-10-02 2008-11-05 Respivert Ltd Novel compound
CA2746357A1 (en) 2008-12-11 2010-06-17 Respivert Limited P38 map kinase inhibitors
SG174134A1 (en) 2009-02-17 2011-10-28 Chiesi Farma Spa Triazolopyridine derivatives as p38 map kinase inhibitors
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
JP2013506691A (ja) * 2009-10-02 2013-02-28 バーテックス ファーマシューティカルズ インコーポレイテッド ホスファチジルイノシトール3−キナーゼのピラゾール阻害薬
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
WO2012054093A2 (en) 2010-01-29 2012-04-26 The Regents Of The University Of California Acyl piperidine inhibitors of soluble epoxide hydrolase
GB201009731D0 (en) 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
MX351958B (es) 2011-12-09 2017-11-06 Chiesi Farm Spa Inhibidores de cinasa.
ME02624B (me) 2011-12-09 2017-06-20 Chiesi Farm Spa Inhibitori kinaze
US9150570B2 (en) * 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
KR20160018567A (ko) 2013-06-06 2016-02-17 키에시 파르마슈티시 엣스. 피. 에이. 키나아제 억제제
WO2017108736A1 (en) 2015-12-23 2017-06-29 Chiesi Farmaceutici S.P.A. N-[3-(3-{4-[[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl} -ureido)-phenyl]-methanesulfonamide derivatives and their use as p38 mapk inhibitors
EP3394059B1 (en) 2015-12-23 2020-11-25 Chiesi Farmaceutici S.p.A. 1-(3-tert-butyl-phenyl)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro- naphthalen-1-yl)-urea derivatives and their use as p38 mapk inhibitors
MA43706B1 (fr) 2016-03-17 2020-09-30 Hoffmann La Roche Dérivé de 5-éthyl-4-méthyl-pyrazole-3-carboxamide ayant une activité en tant qu'agoniste de taar
CN107619388A (zh) 2016-07-13 2018-01-23 南京天印健华医药科技有限公司 作为fgfr抑制剂的杂环化合物
CN107840842A (zh) 2016-09-19 2018-03-27 北京天诚医药科技有限公司 炔代杂环化合物、其制备方法及其在医药学上的应用
WO2019071144A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. USE OF P38 INHIBITORS TO REDUCE DUX4 EXPRESSION
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
TR200102817T2 (tr) 1999-03-12 2002-05-21 Boehringer Ingelheim Pharmaceuticals, Inc. Antiinflamatuar ajanlar olarak faydalı bileşikler
EP1480973B1 (en) * 2002-02-25 2008-02-13 Boehringer Ingelheim Pharmaceuticals Inc. 1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases
GB0320244D0 (en) 2003-05-06 2003-10-01 Aventis Pharma Inc Pyrazoles as inhibitors of tumour necrosis factor
US20070010529A1 (en) * 2003-05-19 2007-01-11 Kanji Takahashi Nitrogenous heterocyclic compounds and medical use thereof

Also Published As

Publication number Publication date
US20080306068A1 (en) 2008-12-11
PL1761520T3 (pl) 2008-12-31
PT1761520E (pt) 2008-09-15
EP1761520B1 (en) 2008-07-09
ATE400567T1 (de) 2008-07-15
SI1761520T1 (sl) 2008-10-31
US7767674B2 (en) 2010-08-03
WO2006009741A1 (en) 2006-01-26
ES2308523T3 (es) 2008-12-01
EP1761520A1 (en) 2007-03-14

Similar Documents

Publication Publication Date Title
DK1761520T3 (da) Kinaseinhibitorer
ATE346070T1 (de) Purinderivate als kinaseinhibitoren
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
CY1109234T1 (el) Αναστολεις κινασης
EA200971051A1 (ru) Ингибиторы p70 s6 киназы
SMT201300109B (it) Imidazopiridazincarbonitrili utili come inibitori di chinasi
TW200640924A (en) VEGF-R2 inhibitors and methods
NO20065148L (no) Monocykliske heterocykler som kinase inhibitorer
CR20120421A (es) Compuestos de aminohetetoarilo o sustituidos con pirazol como inhibidores de proteina quinasa
NO20071127L (no) Triazoloftalaziner
NO20081636L (no) FAP - inhibitorer
EA200801145A1 (ru) Спироциклические производные хиназолина в качестве ингибиторов pde7
EA200801199A1 (ru) Ингибиторы киназы
UY29612A1 (es) Compuestos quimicos ii
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
NI201000059A (es) Inhibidores de la cinasa c-fms.
DE602005025733D1 (de) Pyrazolopyrimidinderivate als inhibitoren der cyclinabhängigen kinase
EA200870409A1 (ru) Антагонисты киназы pi3
IL163777A0 (en) Kinase inhibitors
EA200501928A1 (ru) Пирролодигидроизохинолины как ингибиторы pde10
EA201170680A1 (ru) Ингибиторы акт и p70 s6-киназы
EA201200891A1 (ru) Производные 3,4,4a,10d-тетрагидро-1h-тиопирано[4,3-c]изохинолина
EA200801200A1 (ru) ПРОИЗВОДНЫЕ ПИРАЗОЛИЗОХИНОЛИНМОЧЕВИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ p38 КИНАЗЫ
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина
EA200800070A1 (ru) Производные 2-(1h-индолилсульфанил)ариламина